Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a multinational, randomized, double blind, placebo controlled, parallel group study
comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo.
Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may
be taking approved medication for Alzheimer's disease provided the dose has been stable for
at least 6 months.